{"description":"Only adverse events in relation to the study procedures will be documented and reported. These include adverse events occurring from the MRI scanner, SENC MyoStrain® Testing Software, or breach of confidentiality.","eventGroups":[{"deathsNumAffected":4,"deathsNumAtRisk":25,"description":"* After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring \\>-10% or 9 or more segments \\>-17% for entrance into the study as the Higher Risk Group\n* The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.\n* Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.\n* In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point.","id":"EG000","otherNumAffected":1,"otherNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"title":"MyoStrain® Unblinded Treatment Arm"},{"deathsNumAffected":4,"deathsNumAtRisk":18,"description":"* After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring \\>-10% or 9 or more segments \\>-17% for entrance into the study as the Higher Risk group\n* The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care\n* Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.\n* In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point.","id":"EG001","otherNumAffected":1,"otherNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"title":"MyoStrain® Blinded Control Arm"},{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"-Patients were enrolled but not randomized to either arm.","id":"EG002","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Non-randomized"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (Unspecified)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAtRisk":6}],"term":"Anxiety"}],"timeFrame":"Adverse events and all-cause mortality will be tracked from time of consent to the last study visit (up to 36 months)."}